PARP1 and neoplasm: Using PBMCs as a surrogate for pharmacodynamic effects of PARP inhibitors on tumor has obvious advantages: PBMCs are readily accessible, their collection confers minimal risk to patients, and they allow longitudinal assessment of drug activity over the course of treatment.